Systemic Lupus Erythematosus Clinical Trials

A listing of 45 Systemic Lupus Erythematosus clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Systemic Lupus Erythematosus

13 - 24 of 45

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 45 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Lupus Nephritis Clinical Study

Recruiting

The Ntrust-1 study is part of a broad effort of the global research community to develop more treatment options for people living with lupus nephritis (LN). You may be eligible to participate in this study if you:
 Are 18 to 65 years old.
 Have been diagnosed with lupus nephritis.
 Have received at least two prior therapies for lupus nephritis.

Conditions:

Lupus

Systemic Lupus Erythematosus

Lupus Nephritis

Lupus Erythematosus

Systemic

Learn More

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749

Recruiting

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

Gender:

ALL

Ages:

Between 12 years and 100 years

Trial Updated:

07/28/2025

Locations: Pinnacle Research Group LLC, Anniston, Alabama +107 locations

Pinnacle Research Group LLC, Anniston, Alabama

University of Calif Irvine Med Cntr, Irvine, California

Advanced Medical Research, La Palma, California

University of California LA, Los Angeles, California

Homestead Assoc In Research Inc, Homestead, Florida

IRIS Research and Development, Plantation, Florida

Emory University, Atlanta, Georgia

Willow Rheumatology Wellness, Willowbrook, Illinois

Bluegrass Community Research Inc, Lexington, Kentucky

Accurate Clinical Research, Lake Charles, Louisiana

UMC New Orleans, New Orleans, Louisiana

University Of Maryland, Baltimore, Maryland

Ahmed Arif Medical Research Center, Grand Blanc, Michigan

Washington Univ School Of Medicine, Saint Louis, Missouri

Thomas Jefferson University, Philadelphia, Pennsylvania

West Tennessee Research Institute, Jackson, Tennessee

Novel Research LLC, Bellaire, Texas

Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires

Novartis Investigative Site, La Plata, Buenos Aires

Novartis Investigative Site, Quilmes, Buenos Aires

Novartis Investigative Site, San Miguel, Buenos Aires

Novartis Investigative Site, San Miguel de Tucuman, Tucuman

Novartis Investigative Site, Caba, Not set

Novartis Investigative Site, Tucuman, Not set

Novartis Investigative Site, Maroochydore, Queensland

Novartis Investigative Site, Victoria Park, Western Australia

Novartis Investigative Site, St Leonards, Not set

Novartis Investigative Site, Valdivia, Los Rios

Novartis Investigative Site, Santiago, RM

Novartis Investigative Site, Concepcion, Not set

Novartis Investigative Site, Santiago, Not set

Novartis Investigative Site, Medellin, Antioquia

Novartis Investigative Site, Barranquilla, Atlantico

Novartis Investigative Site, Chia, Cundinamarca

Novartis Investigative Site, Bucaramanga, Santander

Novartis Investigative Site, Cali, Valle Del Cauca

Novartis Investigative Site, Bogota, Not set

Novartis Investigative Site, Angers Cedex 9, Not set

Novartis Investigative Site, Grenoble, Not set

Novartis Investigative Site, Montpellier 5, Not set

Novartis Investigative Site, Paris, Not set

Novartis Investigative Site, Toulouse, Not set

Novartis Investigative Site, Tours, Not set

Novartis Investigative Site, Leipzig, Sachsen

Novartis Investigative Site, Aachen, Not set

Novartis Investigative Site, Berlin, Not set

Novartis Investigative Site, Erlangen, Not set

Novartis Investigative Site, Freiburg, Not set

Novartis Investigative Site, Herne, Not set

Novartis Investigative Site, Koeln, Not set

Novartis Investigative Site, Mainz, Not set

Novartis Investigative Site, Muenchen, Not set

Novartis Investigative Site, New Delhi, Delhi

Novartis Investigative Site, Ahmedabad, Gujarat

Novartis Investigative Site, Kozhikode, Kerala

Novartis Investigative Site, Kolhapur, Maharashtra

Novartis Investigative Site, Nagpur, Maharashtra

Novartis Investigative Site, Nashik, Maharashtra

Novartis Investigative Site, Pune, Maharashtra

Novartis Investigative Site, Secunderabad, Telangana

Novartis Investigative Site, Dehradun, Uttarakhand

Novartis Investigative Site, New Delhi, Not set

Novartis Investigative Site, Puducherry, Not set

Novartis Investigative Site, Visakhapatnam, Not set

Novartis Investigative Site, Ancona, AN

Novartis Investigative Site, Caserta, CE

Novartis Investigative Site, Cona, FE

Novartis Investigative Site, Padova, PD

Novartis Investigative Site, Pisa, PI

Novartis Investigative Site, Roma, RM

Novartis Investigative Site, Torino, TO

Novartis Investigative Site, Milano, Not set

Novartis Investigative Site, Daejeon, Korea

Novartis Investigative Site, Seoul, Seocho Gu

Novartis Investigative Site, Gwangju Gwangyeoksi, Not set

Novartis Investigative Site, Seoul, Not set

Novartis Investigative Site, Seremban, Negeri Sembilan

Novartis Investigative Site, Ipoh, Perak

Novartis Investigative Site, Kuching, Sarawak

Novartis Investigative Site, Petaling Jaya, Selangor Darul Ehsan

Novartis Investigative Site, Kuala Lumpur, Not set

Novartis Investigative Site, Selangor Darul Ehsan, Not set

Novartis Investigative Site, Ciudad de Mexico, Distrito Federal

Novartis Investigative Site, Leon, Guanajuato

Novartis Investigative Site, Guadalajara, Jalisco

Novartis Investigative Site, Morelia, Michoacan

Novartis Investigative Site, Merida, Yucatan

Novartis Investigative Site, Mexico, Not set

Novartis Investigative Site, Afumati, Ilfov

Novartis Investigative Site, Brasov, Not set

Novartis Investigative Site, Bucuresti, Not set

Novartis Investigative Site, Cluj Napoca, Not set

Novartis Investigative Site, Kaohsiung, Not set

Novartis Investigative Site, Taichung, Not set

Novartis Investigative Site, Taipei, Not set

Novartis Investigative Site, Taoyuan, Not set

Novartis Investigative Site, Birmingham, Not set

Novartis Investigative Site, Leicester, Not set

Novartis Investigative Site, London, Not set

Conditions: Systemic Lupus Erythematosus

Learn More ›

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114

Recruiting

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

Gender:

ALL

Ages:

Between 12 years and 100 years

Trial Updated:

07/28/2025

Locations: University of Arizona Cancer Center, Tucson, Arizona +179 locations

University of Arizona Cancer Center, Tucson, Arizona

Providence Medical Center, Burbank, California

University of California San Diego, La Jolla, California

Keck School of Medicine, Los Angeles, California

Millennium Clinical Trials, Westlake Village, California

University of Colorado, Aurora, Colorado

Yale University School Of Medicine, New Haven, Connecticut

Stamford Hospital, Stamford, Connecticut

Clinical Res Of W Florida, Clearwater, Florida

GNP Research, Cooper City, Florida

University Of Miami, Miami, Florida

Clinical Research of West Florida Inc, Tampa, Florida

Parris and Associates Rheumatology, Lawrenceville, Georgia

Chicago Clinical Research Inst, Chicago, Illinois

Robert A Hozman MD SC, Skokie, Illinois

Lake Cumberland Rheumatology and In, New Albany, Indiana

Ochsner Clinic Foundation, Baton Rouge, Louisiana

Henry Ford Health, Detroit, Michigan

Univ of Nevada School of Med, Las Vegas, Nevada

Innovative Health Research, Las Vegas, Nevada

Sahni Rheumatology and Therapy, West Long Branch, New Jersey

NYU Langone Health, Brooklyn, New York

Medical Center Main Campus, Cleveland, Ohio

STAT Research Inc, Dayton, Ohio

Paramount Med Rsrch and Consult LLC, Middleburg Heights, Ohio

University Of Pittsburgh, Pittsburgh, Pennsylvania

Prisma Health, Columbia, South Carolina

Shelby Research LLC, Memphis, Tennessee

Accurate Clinical Research Research, Baytown, Texas

Texas Arthritis Center, El Paso, Texas

Epic Medical Research, Red Oak, Texas

Novartis Investigative Site, Salvador, BA

Novartis Investigative Site, Brasilia, DF

Novartis Investigative Site, Vitoria, ES

Novartis Investigative Site, Belo Horizonte, MG

Novartis Investigative Site, Curitiba, PR

Novartis Investigative Site, Natal, Rio Grande Do Norte

Novartis Investigative Site, Niteroi, RJ

Novartis Investigative Site, Rio de Janeiro, RJ

Novartis Investigative Site, Barretos, Sao Paulo

Novartis Investigative Site, Sao Paulo, SP

Novartis Investigative Site, Salvador, Not set

Novartis Investigative Site, Plovdiv, Not set

Novartis Investigative Site, Ruse, Not set

Novartis Investigative Site, Sofia, Not set

Novartis Investigative Site, Calgary, Alberta

Novartis Investigative Site, Edmonton, Alberta

Novartis Investigative Site, Vancouver, British Columbia

Novartis Investigative Site, Hamilton, Ontario

Novartis Investigative Site, Toronto, Ontario

Novartis Investigative Site, Rimouski, Quebec

Novartis Investigative Site, Guangzhou, Guangdong

Novartis Investigative Site, Shantou, Guangdong

Novartis Investigative Site, Haikou, Hainan

Novartis Investigative Site, Zhuzhou, Hunan

Novartis Investigative Site, Baotou, Inner Mongolia

Novartis Investigative Site, Nanjing, Jiangsu

Novartis Investigative Site, Suzhou, Jiangsu

Novartis Investigative Site, Nanchang, Jiangxi

Novartis Investigative Site, Pingxiang, Jiangxi

Novartis Investigative Site, Chang Chun, Jilin

Novartis Investigative Site, Linyi, Shandong

Novartis Investigative Site, Chengdu, Sichuan

Novartis Investigative Site, Urumqi, Xinjiang

Novartis Investigative Site, Wenzhou, Zhejiang

Novartis Investigative Site, Beijing, Not set

Novartis Investigative Site, Shanghai, Not set

Novartis Investigative Site, Wuhan, Not set

Novartis Investigative Site, Xinxiang, Not set

Novartis Investigative Site, Zhejiang, Not set

Novartis Investigative Site, Cali, Valle Del Cauca

Novartis Investigative Site, Brno, Not set

Novartis Investigative Site, Praha 2, Not set

Novartis Investigative Site, Uherske Hradiste, Not set

Novartis Investigative Site, Guatemala City, Not set

Novartis Investigative Site, Guatemala, Not set

Novartis Investigative Site, Szekesfehervar, Fejer

Novartis Investigative Site, Budapest, Not set

Novartis Investigative Site, Gyula, Not set

Novartis Investigative Site, Zalaegerszeg, Not set

Novartis Investigative Site, Haifa, Not set

Novartis Investigative Site, Ramat Gan, Not set

Novartis Investigative Site, Nagoya, Aichi

Novartis Investigative Site, Ichikawa, Chiba

Novartis Investigative Site, Fukuoka city, Fukuoka

Novartis Investigative Site, Kitakyushu, Fukuoka

Novartis Investigative Site, Sapporo city, Hokkaido

Novartis Investigative Site, Ono, Hyogo

Novartis Investigative Site, Kawasaki, Kanagawa

Novartis Investigative Site, Yokohama, Kanagawa

Novartis Investigative Site, Sendai city, Miyagi

Novartis Investigative Site, Kurashiki, Okayama

Novartis Investigative Site, Suita, Osaka

Novartis Investigative Site, Iruma-gun, Saitama

Novartis Investigative Site, Bunkyo ku, Tokyo

Novartis Investigative Site, Bunkyo-ku, Tokyo

Novartis Investigative Site, Chuo ku, Tokyo

Novartis Investigative Site, Fuchu-city, Tokyo

Novartis Investigative Site, Fuchu, Tokyo

Novartis Investigative Site, Itabashi-ku, Tokyo

Novartis Investigative Site, Meguro, Tokyo

Novartis Investigative Site, Shinjuku-ku, Tokyo

Novartis Investigative Site, Chiba, Not set

Novartis Investigative Site, Fukuoka, Not set

Novartis Investigative Site, Gifu, Not set

Novartis Investigative Site, Miyazaki, Not set

Novartis Investigative Site, Osaka, Not set

Novartis Investigative Site, Wroclaw, Dolnoslaskie

Novartis Investigative Site, Bydgoszcz, Not set

Novartis Investigative Site, Bytom, Not set

Novartis Investigative Site, Lodz, Not set

Novartis Investigative Site, Rzeszow, Not set

Novartis Investigative Site, Warszawa, Not set

Novartis Investigative Site, Braga, Not set

Novartis Investigative Site, Leiria, Not set

Novartis Investigative Site, Lisboa, Not set

Novartis Investigative Site, Vila Nova De Gaia, Not set

Novartis Investigative Site, Singapore, Not set

Novartis Investigative Site, Bratislava, Not set

Novartis Investigative Site, Kosice, Not set

Novartis Investigative Site, Piestany, Not set

Novartis Investigative Site, Zvolen, Not set

Novartis Investigative Site, Cape Town, Not set

Novartis Investigative Site, Panorama, Not set

Novartis Investigative Site, Pretoria, Not set

Novartis Investigative Site, Stellenbosch, Not set

Novartis Investigative Site, Umhlanga, Not set

Novartis Investigative Site, Elche, Alicante

Novartis Investigative Site, Vitoria Gasteiz, Araba

Novartis Investigative Site, Santander, Cantabria

Novartis Investigative Site, Badalona, Catalunya

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Badajoz, Extremadura

Novartis Investigative Site, Merida, Extremadura

Novartis Investigative Site, Santiago De Compostela, Galicia

Novartis Investigative Site, San Sebastian de los Reyes, Madrid

Novartis Investigative Site, El Palmar, Murcia

Novartis Investigative Site, Pamplona, Navarra

Novartis Investigative Site, Vigo, Pontevedra

Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife

Novartis Investigative Site, Madrid, Not set

Novartis Investigative Site, Valencia, Not set

Novartis Investigative Site, Valladolid, Not set

Novartis Investigative Site, Songkhla, Hat Yai

Novartis Investigative Site, Bangkok, Not set

Novartis Investigative Site, Chiang Mai, Not set

Novartis Investigative Site, Muang, Not set

Novartis Investigative Site, Ankara, Not set

Novartis Investigative Site, Aydin, Not set

Novartis Investigative Site, Etlik Ankara, Not set

Novartis Investigative Site, Istanbul, Not set

Novartis Investigative Site, Izmir, Not set

Novartis Investigative Site, Konak-Izmir, Not set

Novartis Investigative Site, Konya, Not set

Novartis Investigative Site, Talas Kayseri, Not set

Conditions: Systemic Lupus Erythematosus

Learn More ›

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365

Recruiting

The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

07/28/2025

Locations: Pinnacle Research Group Llc, Anniston, Alabama +36 locations

Pinnacle Research Group Llc, Anniston, Alabama

Providence Medical Foundation, Fullerton, California

Advanced Medical Research, La Palma, California

Conquest Research, Winter Park, Florida

Parris and Associates Rheumatology, Lawrenceville, Georgia

Indiana Univ School of Dentistry, Indianapolis, Indiana

Ochsner Health System, Baton Rouge, Louisiana

Ahmed Arif Medical Research Center, Grand Blanc, Michigan

Paramount Med Rsrch and Consult LLC, Middleburg Heights, Ohio

RAO Research LLS, Oklahoma City, Oklahoma

Altoona Center for Clin Res, Duncansville, Pennsylvania

West Tennessee Research Institute, Jackson, Tennessee

Shelby Research LLC, Memphis, Tennessee

Novel Research LLC, Bellaire, Texas

Southwest Rheum Rsrch LLC, Mesquite, Texas

Uni of Texas Health Science Center, San Antonio, Texas

Advanced Rheumatology of Houston, Spring, Texas

Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires

Novartis Investigative Site, Quilmes, Buenos Aires

Novartis Investigative Site, Tucuman, San Miguel De Tucuman

Novartis Investigative Site, Buenos Aires, Not set

Novartis Investigative Site, Hamilton, Ontario

Novartis Investigative Site, Toronto, Ontario

Novartis Investigative Site, Rimouski, Quebec

Novartis Investigative Site, Trois Rivieres, Quebec

Novartis Investigative Site, Brno, Not set

Novartis Investigative Site, Praha 2, Not set

Novartis Investigative Site, Uherske Hradiste, Not set

Novartis Investigative Site, Budapest, Not set

Novartis Investigative Site, Debrecen, Not set

Novartis Investigative Site, Salerno, SA

Novartis Investigative Site, Krakow, Not set

Novartis Investigative Site, Lublin, Not set

Novartis Investigative Site, Santiago De Compostela, Galicia

Novartis Investigative Site, A Coruna, Not set

Novartis Investigative Site, Madrid, Not set

Conditions: Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis

Learn More ›

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163

Recruiting

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

07/25/2025

Locations: Sierra Pacific Arthritis and Rheumatology Centers, Fresno, California +81 locations

Sierra Pacific Arthritis and Rheumatology Centers, Fresno, California

California Research Institute, Huntington Park, California

University of California, San Diego, La Jolla, California

Clinical Research of West Florida, Inc, Clearwater, Florida

Clinical Research of West Florida, Inc., Tampa, Florida

Emory University, Atlanta, Georgia

Accurate Clinical Research, Lake Charles, Louisiana

Henry Ford Hospital, Detroit, Michigan

June DO, PC, Lansing, Michigan

Juno DO, PC, Lansing, Michigan

DJL Clinical Research PLLC, Charlotte, North Carolina

Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

Penn State - Hershey Medical Center, Hershey, Pennsylvania

Prolato Clinical Research Center (PCRC), Houston, Texas

Accurate Clinical Research, Houston, Texas

Prime Clinical Research - Mansfield, Mansfield, Texas

CHU de Liege, Liege, Not set

Medical Center Medtech Services EOOD, Haskovo, Not set

University Multiprofile Hospital for Active Treatment "Eurohospital Plovdiv", Plovdiv, Not set

Richmond Clinical Trials, Richmond, British Columbia

Riverside Professional Centre, Sydney, Nova Scotia

Anhui Provincial Hospital (The First Affiliated Hospital of USTC), Hefei, Anhui

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing

Peking University People's Hospital, Beijing, Beijing

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong

Shenzhen People's Hospital, Shenzhen, Guangdong

The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei

The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangx

Lanzhou University Second Hospital, Pudong, Shanghai

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai

The Second Affiliated Hospital of Soochow University, Suzhou, Not set

Shanxi Bethune Hospital, Taiyuan, Not set

The First Affiliated Hospital of Ziamen University, Xiamen, Not set

Sjaellands Universitetshospital, Koge, Koge, Not set

Medicover Munchen Ost MVZ, München, Bavaria

Uniklinik Koln, Cologne, Not set

Attikon University General Hospital, Chaidari, Athens

General Hospital Asklepieio Voulas, Voula, Athens

University General Hospital of Heraklion, Heraklion, Not set

Olympion General Clinic, Patras, Not set

General Hospital of Thessaloniki ''Hippokration'', Thessaloniki, Not set

Kianous Stavros, Thessaloníki, Not set

Policlinico Universitario Campus Biomedico Di Roma, Roma, Not set

Centro Ricerche Cliniche Di Verona S.r.l., Verona, Not set

Hospital of Japan Community Health Care Organization Chukyo Hospital, Nagoya-shi, Aichi

Hospital of the University of Occupational and Environmental Health, Kitakyushu-shi, Fukuoka

Hospital of Shinkenko Clinic, Naha-city, Okinawa

Hokkaido University Hospital, Kita-Ku, Sapporo Hokkaido

Juntendo University Hospital, Bunkyō-Ku, Not set

Clinstile, S.A. de C.V., Mexico City, Cuidad de Mexico

PanAmerican Clinical Research, Guadalajara, Jalisco

Eme Red Hospitalaria, Merida, Yucatán

Kohler and Milsten Research, Merida, Yucatán

Oaxaca Site Management Organization, Oaxaca, Not set

Centrum Medyczne Plejady, Krakow, Malopolskie

MICS Centrum Medyczne Warszawa, Warsaw, Mazowieckie

Prywatna Praktyka Lekarska Prof Hab Med Pawel Hrycaj, Poznan, Wielkopolskie

MICS Centrum Medyczne Bydgoszcz, Bydgoszcz, Not set

Krakowskie Centrum Medyczne, Krakow, Not set

SOMED CR, Lodz, Not set

SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz, Not set

Pracownia Badan Klinicznych Salus, Wroclaw, Not set

ULS de Santa Maria, EPE - Hospital de Santa Maria, Lisboa, Not set

Hospital Egas Moniz, Lisbon, Not set

ULS da Arrábida, E.P.E. - Hospital de São Bernardo, Setúbal, Not set

Centro Reumatologico de Caguas, Caguas, Not set

Latin Clinical Trial Center, San Juan, Not set

Centrul Medical de Diagnostic si Tratament Ambulator NEOMED SRL, Brasov, Not set

Dr I Cantacuzino Clinical Hospital, Bucharest, Not set

FARMOVS, Bloemfontein, Not set

Panorama Medical Centre, Cape Town, Not set

FutureMeds DKF, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Virgen del Rocío, Sevilla, Not set

Buddhist Tzu Chi General Hospital, Chiayi City, Not set

Kaohsiung Veterans General Hospital, Kaohsiung City, Not set

Chung Shan Medical University Hospital, Taichung, Not set

Taipei Veterans General Hospital, Taipei City, Not set

Taipei Medical University Hospital, Taipei, Not set

Chang Gung Memorial Hospital, Taoyuan, Not set

Conditions: Systemic Lupus Erythematosus

Learn More ›

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

NCT03816345

Recruiting

This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Stanford Cancer Institute Palo Alto, Palo Alto, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut

Yale University, New Haven, Connecticut

MedStar Georgetown University Hospital, Washington, District of Columbia

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Northwestern University, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

University of Kansas Clinical Research Center, Fairway, Kansas

HaysMed, Hays, Kansas

University of Kansas Cancer Center, Kansas City, Kansas

Lawrence Memorial Hospital, Lawrence, Kansas

The University of Kansas Cancer Center - Olathe, Olathe, Kansas

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas

University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas

Mercy Hospital Pittsburg, Pittsburg, Kansas

Salina Regional Health Center, Salina, Kansas

University of Kansas Health System Saint Francis Campus, Topeka, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland

National Institutes of Health Clinical Center, Bethesda, Maryland

Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan

Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

University Health Truman Medical Center, Kansas City, Missouri

University of Kansas Cancer Center - North, Kansas City, Missouri

University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Siteman Cancer Center-South County, Saint Louis, Missouri

Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri

Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

NYU Langone Hospital - Long Island, Mineola, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

NYP/Weill Cornell Medical Center, New York, New York

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas

M D Anderson Cancer Center, Houston, Texas

UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

University Health Network-Princess Margaret Hospital, Toronto, Ontario

Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm

Learn More ›

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043

Recruiting

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/24/2025

Locations: Climb Bio Investigative Site #100101, San Antonio, Texas +7 locations

Conditions: Systemic Lupus Erythematosus

Learn More ›

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

NCT06518668

Recruiting

Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/22/2025

Locations: Columbia University Irving Medical Center, New York, New York

Conditions: Systemic Lupus Erythematosus

Learn More ›

Intervention to Improve Communication and Medication Adherence in Lupus

NCT06458075

Recruiting

CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the following: 1. clinicians will be provided with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill date, engage and formulate solutions to... Read More

Gender:

ALL

Ages:

Between 18 years and 90 years

Trial Updated:

07/18/2025

Locations: Duke University, Durham, North Carolina

Conditions: Systemic Lupus Erythematosus

Learn More ›

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363

Recruiting

The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis

Learn More ›

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310

Recruiting

A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE

Gender:

ALL

Ages:

Between 5 years and 17 years

Trial Updated:

07/18/2025

Locations: Research Site, Phoenix, Arizona +91 locations

Research Site, Phoenix, Arizona

Research Site, Los Angeles, California

Research Site, Washington, District of Columbia

Research Site, Chicago, Illinois

Research Site, Bethesda, Maryland

Research Site, Saint Paul, Minnesota

Research Site, Bronx, New York

Research Site, New Hyde Park, New York

Research Site, New York, New York

Research Site, Valhalla, New York

Research Site, Durham, North Carolina

Research Site, Cincinnati, Ohio

Research Site, Cleveland, Ohio

Research Site, Columbus, Ohio

Research Site, Portland, Oregon

Research Site, Philadelphia, Pennsylvania

Research Site, Greenville, South Carolina

Research Site, El Paso, Texas

Research Site, Houston, Texas

Research Site, Salt Lake City, Utah

Research Site, Buenos Aires, Not set

Research Site, Córdoba, Not set

Research Site, Rosario, Not set

Research Site, Botucatu, Not set

Research Site, Curitiba, Not set

Research Site, Porto Alegre, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Sao Paulo, Not set

Research Site, São Paulo, Not set

Research Site, Vancouver, British Columbia

Research Site, Toronto, Ontario

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Shanghai, Not set

Research Site, Suzhou, Not set

Research Site, Wenzhou, Not set

Research Site, Zhengzhou, Not set

Research Site, Barranquilla, Not set

Research Site, Medellin, Not set

Research Site, Bordeaux, Not set

Research Site, Bron, Not set

Research Site, Le Kremlin-Bicêtre, Not set

Research Site, LILLE Cedex, Not set

Research Site, Toulouse, Not set

Research Site, Berlin, Not set

Research Site, Freiburg, Not set

Research Site, Sankt Augustin, Not set

Research Site, Genova, Not set

Research Site, Milano, Not set

Research Site, Padova, Not set

Research Site, Roma, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chiba, Not set

Research Site, Fuchu-shi, Not set

Research Site, Kawasaki-shi, Not set

Research Site, Kobe-shi, Not set

Research Site, Obu-shi, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Yokohama-shi, Not set

Research Site, Guadalajara, Not set

Research Site, Merida, Not set

Research Site, Mexico, Not set

Research Site, Monterrey, Not set

Research Site, Toluca, Not set

Research Site, Lodź, Not set

Research Site, Warszawa, Not set

Research Site, Wroclaw, Not set

Research Site, Lisboa, Not set

Research Site, Porto, Not set

Research Site, Cape Town, Not set

Research Site, Esplugues de Llobregat, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Valencia, Not set

Research Site, Ankara, Not set

Research Site, İstanbul, Not set

Research Site, Kayseri, Not set

Research Site, Umraniye, Not set

Research Site, Birmingham, Not set

Research Site, Bristol, Not set

Research Site, Liverpool, Not set

Research Site, London, Not set

Research Site, Manchester, Not set

Research Site, Southampton, Not set

Conditions: Systemic Lupus Erythematosus

Learn More ›

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297

Recruiting

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/18/2025

Locations: University of California Irvine, Orange, California +21 locations

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis

Learn More ›

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

NCT06594068

Recruiting

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PRIMULA Lac) is a Post Marketing Requirements (PMR) study designed to fulfill the FDA post-marketing requirements. The study will collect data about the presence of anifrolumab in human breast milk and serum (maternal and infant) among lactating individuals who receive anifrolumab therapeutically.

Gender:

FEMALE

Ages:

Between 18 years and 130 years

Trial Updated:

07/15/2025

Locations: Research Site, Las Vegas, Nevada

Conditions: Systemic Lupus Erythematosus

Learn More ›

13 - 24 of 45